Dimethyl fumarate associated lymphopenia in clinical practice.
about
Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapyProgressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarateReduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarateLymphocyte subtypes in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarateDimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patientsCharacterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerationsNonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarateEfficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis.Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation.Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence.Lymphopenia and fumaric acid esters for psoriasis: a retrospective case series prompted by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) recommendations.[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
P2860
Q26738969-629D7800-398D-4FE3-8123-345A72EB29F4Q28083338-897A8E78-F531-4998-9BB8-925077241F4BQ28388243-56FD614A-462F-4808-8FAF-A8C6D377AD6EQ33613102-0BF99B90-E3FC-4D9C-A159-F33EBC7C59E8Q36257412-7E3D7593-359D-43AE-BDE2-7DB58D9A6EE7Q36379001-ABB6EBA4-5D74-44C6-8872-6FBE8945871BQ36429919-218A5B9F-0419-4C3B-9E10-2370058390DCQ36792169-C94D0433-6DDE-49A7-BE9E-A907C1F900C5Q37008832-5FD1F86C-BFC2-44AD-AFB3-577F63D45B95Q37201023-30FB95AD-78F8-49A1-9256-CA339954AC9CQ37343648-3043BD47-C375-41D9-B283-4BFA37CC3976Q40747927-B4C9A284-11A8-4956-A341-45617AA74DE5Q41676658-9BDC396C-3370-4950-A459-1066092316FAQ46650963-08BE0ECD-A5F9-4748-8BAF-2009EF788314Q48191914-E45E5CBD-9F4C-408D-92D0-A6473CB7CF00Q52855510-ECE44620-BF63-48EA-A862-22FCCE3B2FEAQ53338098-7E41CD29-825B-44E2-A909-78527FBF5533
P2860
Dimethyl fumarate associated lymphopenia in clinical practice.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Dimethyl fumarate associated lymphopenia in clinical practice.
@ast
Dimethyl fumarate associated lymphopenia in clinical practice.
@en
type
label
Dimethyl fumarate associated lymphopenia in clinical practice.
@ast
Dimethyl fumarate associated lymphopenia in clinical practice.
@en
prefLabel
Dimethyl fumarate associated lymphopenia in clinical practice.
@ast
Dimethyl fumarate associated lymphopenia in clinical practice.
@en
P2860
P356
P1476
Dimethyl fumarate associated lymphopenia in clinical practice
@en
P2093
Erin E Longbrake
P2860
P304
P356
10.1177/1352458514559299
P577
2014-11-28T00:00:00Z